Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07053436 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Horizon Two: HR NDMM (MMRC-100)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 7 → 12 locations Eligibility criteria expanded, about 17 words · Secondary endpoints: details revised at 4 of 7 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 4 of 7 entries
  2. Trial sites expanded: 4 → 7 locationsv4
  3. Study sites: 2 to 4 Study title shortened, about 7 wordsv3 Show 1 more changeShow less
    • Study title shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 1, 2025 to Apr 30, 2026 · Study sites: 0 to 2v2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 1, 2025 to Apr 30, 2026
    • Study sites: 0 to 2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.
Trial Details
NCT Number NCT07053436
Lead Sponsor Multiple Myeloma Research Consortium
Conditions High Risk Newly Diagnosed Multiple Myeloma
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov